Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375894 | 0.87 | DGAT1 (0.40) | DGAT1AKT1EGFRIGF1RSRC | |
| SCHEMBL29930779 | 0.82 | AXL (0.41) | DGAT1SRCFLT4KDRFLT3 | |
| SCHEMBL1592834 | 0.81 | MERTK (0.39) | DGAT1IGF1RFLT4KDRFLT3 | |
| SCHEMBL29930401 | 0.81 | DYRK1B (0.40) | DGAT1SRCKDRFLT3PDE1B | |
| SCHEMBL29930815 | 0.80 | AXL (0.41) | DGAT1EGFRSRCKDREPHB4 | |
| SCHEMBL3490706 | 0.79 | AKT1 (0.33) | AKT1MAOBPDE1BALOX5AP | |
| SCHEMBL27193468 | 0.79 | DGAT1 (0.37) | DGAT1PDE1BGSK3B | |
| SCHEMBL29930809 | 0.79 | DGAT1 (0.37) | DGAT1SRCKDRFLT3 | |
| SCHEMBL3490473 | 0.78 | DGAT1 (0.42) | DGAT1PDE10AALOX5AP | |
| SCHEMBL3490212 | 0.78 | DGAT1 (0.38) | DGAT1EGFRALOX5APGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| EP-2134179-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | DGAT1 3371/4885AKT1 148/4885EGFR 574/4885 |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | MAP3K20, TTK, MAP3K19 | DGAT1 3371/4885AKT1 148/4885EGFR 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.